
ARS Pharmaceuticals Inc
NASDAQ:SPRY

Intrinsic Value
The intrinsic value of one
SPRY
stock under the Base Case scenario is
17.56
USD.
Compared to the current market price of 17.28 USD,
ARS Pharmaceuticals Inc
is
Undervalued by 2%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
ARS Pharmaceuticals Inc
Fundamental Analysis


Revenue & Expenses Breakdown
ARS Pharmaceuticals Inc
Balance Sheet Decomposition
ARS Pharmaceuticals Inc
Current Assets | 303.9m |
Cash & Short-Term Investments | 275.7m |
Receivables | 10.3m |
Other Current Assets | 17.9m |
Non-Current Assets | 23.5m |
PP&E | 1.1m |
Intangibles | 7.2m |
Other Non-Current Assets | 15.1m |
Free Cash Flow Analysis
ARS Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
ARS Pharmaceuticals Inc
Revenue
|
97.1m
USD
|
Cost of Revenue
|
-2.6m
USD
|
Gross Profit
|
94.6m
USD
|
Operating Expenses
|
-121.6m
USD
|
Operating Income
|
-27.1m
USD
|
Other Expenses
|
11.4m
USD
|
Net Income
|
-15.7m
USD
|
SPRY Profitability Score
Profitability Due Diligence
ARS Pharmaceuticals Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

Score
ARS Pharmaceuticals Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.
SPRY Solvency Score
Solvency Due Diligence
ARS Pharmaceuticals Inc's solvency score is 79/100. The higher the solvency score, the more solvent the company is.

Score
ARS Pharmaceuticals Inc's solvency score is 79/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SPRY Price Targets Summary
ARS Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
SPRY
is 32.23 USD
with a low forecast of 26.26 USD and a high forecast of 42 USD.
Dividends
Current shareholder yield for SPRY is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
SPRY
stock under the Base Case scenario is
17.56
USD.
Compared to the current market price of 17.28 USD,
ARS Pharmaceuticals Inc
is
Undervalued by 2%.